Eye DisordersPhase 4APPRAISENCT07434635
APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes
A Phase 4 study testing Atropine 1% in people with Eye Disorders, run by University of California, San Francisco at 1 site in United States.
Trial summary
The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Eye Disorders
- What is being tested?
- Atropine 1%
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Mar 2026to Feb 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patient undergoing vitrectomy surgery
- able to give informed consent
Who cannot join
- post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications
- subjects with altered post-operative eyedrop schedule for enhanced inflammation control
- documented allergy to atropine
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California, San Francisco
San Francisco, California, 94143
Jay Stewart, 415-353-9635, eyestudy@ucsf.edu
About this study
The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries.
Read the detailed description
Atropine eyedrops are often used after certain eye surgeries. This study will compare several outcomes following surgery in patients either using or not using this treatment.
- Conditions
- Eye Disorders
- Being tested
- Atropine 1%
- Keywords
- atropine, eye surgery
- Medical subject headings
- Eye Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atropine 1%Drug
Also called Atropine
Subtraction of atropine eyedrops from post-operative treatment regimen
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | No atropine |
| Experimental | Experimental | Participant uses atropine eyedrops Receives: Drug: Atropine 1% |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain score on the Visual Analog Scale (VAS)
Whether atropine use impacts post-operative pain score on the standard Visual Analog Scale (VAS)
Measured: 1 month
Secondary outcomes (5)
Anterior chamber inflammation (aqueous cell and flare)
Whether atropine impacts the occurrence of post-operative inflammation, quantified as aqueous cell and flare, using the Standardization of Uveitis Nomenclature (SUN) Criteria
Measured: 1 month
Cystoid macular edema detected by optical coherence tomography
Whether atropine impacts the occurrence of cystoid macular edema after surgery, detected by optical coherence tomography scanning of the retina
Measured: 1 month
Time to visual recovery
Whether atropine impacts the time to visual recovery
Measured: 1 month
Intraocular pressure
Whether atropine impacts intraocular pressure after surgery
Measured: 1 month
Posterior synechiae formation
Presence or absence of posterior synechiae assessed by slit lamp examination at post-operative visits
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start10 Mar 2026
- Primary completionFeb 2028 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eye DisordersStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 62 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jay Stewart, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07434635
- Sponsor's protocol ID
- 25-45406
- Acronym
- APPRAISE
- Status last verified
- Jul 2026
- First submitted
- 5 Feb 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes
- ClinicalTrials.gov ID
- NCT07434635
- Acronym / sponsor ID
- APPRAISE / 25-45406
- Conditions
- Eye Disorders
- Keywords
- atropine, eye surgery
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 62 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 10 Mar 2026 (actual)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries.
Detailed description
Atropine eyedrops are often used after certain eye surgeries. This study will compare several outcomes following surgery in patients either using or not using this treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –No atropine |
| Experimental | Experimental | Drug: Atropine 1%Participant uses atropine eyedrops |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- patient undergoing vitrectomy surgery
- able to give informed consent
Key exclusion criteria (3 listed)
- post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications
- subjects with altered post-operative eyedrop schedule for enhanced inflammation control
- documented allergy to atropine
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atropine 1%Also: AtropineSubtraction of atropine eyedrops from post-operative treatment regimen | Drug | Experimental |
Primary outcome
Pain score on the Visual Analog Scale (VAS)
Time frame: 1 month
Whether atropine use impacts post-operative pain score on the standard Visual Analog Scale (VAS)
5 secondary outcomes
Anterior chamber inflammation (aqueous cell and flare)
Time frame: 1 month
Cystoid macular edema detected by optical coherence tomography
Time frame: 1 month
Time to visual recovery
Time frame: 1 month
Intraocular pressure
Time frame: 1 month
Posterior synechiae formation
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Eye Disorders
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
Recruiting
Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial
Pre-myopia, Myopia
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jay Stewart, MD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Atropine 1% in people with Eye Disorders, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jay Stewart, MD (415-353-9635, eyestudy@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain score on the Visual Analog Scale (VAS) (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.